Claims
- 1. A compound which is a member of the group consisting of a free organic base of the formula ##STR14## wherein R.sup.1 is a hydrogen atom, alkyl having from 1 to 4 carbons, fluoro or chloro;
- R.sup.2 is a hydrogen atom, alkyl having from 1 to 4 carbons, alkoxy having from 1 to 4 carbons, fluoro or chloro;
- R.sup.3 is a hydrogen atom, alkyl having from 1 to 4 carbons, alkoxy having from 1 to 4 carbons, fluoro or chloro;
- A is ##STR15## and B is an unsubstituted pyridyl radical which may be attached at its 2-, 3- or 4- position, and
- pharmaceutically acceptable acid addition salts thereof; provided that when R.sup.2 and R.sup.3 are on adjacent carbons they are not both alkyl or alkoxy which are branched.
- 2. A compound of claim 1 in which R.sup.1 is a hydrogen atom.
- 3. A compound of claim 2 in which each of R.sup.2 and R.sup.3 is a hydrogen atom.
- 4. A compound of claim 2 in which at least one of R.sup.2 and R.sup.3 is t.-butyl.
- 5. The compound of claim 4 which is 4-(3',5'-di-tert.-butylphenoxy)-phenyl nicotinyl ketone.
- 6. The compound of claim 1 which is p-phenoxyphenyl 2-pyridyl ketone.
- 7. The compound of claim 1 which is p-phenoxyphenyl 4-pyridyl ketone.
- 8. A compound of claim 1 in which B is a 3-pyridyl radical.
- 9. A compound of claim 1 in which B is a 4-pyridyl radical.
- 10. A compound of claim 1 in which B is a 2-pyridyl radical.
- 11. The compound of claim 5 which is p-phenoxyphenyl nicotinyl ketone.
- 12. A pharmaceutical composition, useful in treating lipidemia, comprising a compound which is a member of the group consisting of a free organic base of the formula ##STR16## wherein R.sup.1 is a hydrogen atom, alkyl having from 1 to 4 carbons, fluoro or chloro;
- R.sup.2 is a hydrogen atom, alkyl having from 1 to 4 carbons, alkoxy having from 1 to 4 carbons, fluoro or chloro;
- R.sup.3 is a hydrogen atom, alkyl having from 1 to 4 carbons, alkoxy having from 1 to 4 carbons, fluoro or chloro;
- A is ##STR17## , and
- B is an unsubstituted pyridyl radical which may be attached at its 2-, 3- or 4- position, and a
- pharmaceutically acceptable acid addition salt thereof; provided that when R.sup.2 and R.sup.3 are on adjacent carbons they are not both alkyl or alkoxy which are branched, and a pharmaceutically-acceptable solid carrier.
- 13. A composition of claim 12 in which B of the compound is a 3-pyridyl radical.
- 14. A composition of claim 12 in unit dose form in which the compound is present in an amount of from about 75 to 1500 milligrams.
- 15. A composition of claim 12 in the form of a capsule.
- 16. The composition of claim 12 in the form of a tablet.
- 17. A composition of claim 12 in which the compound is p-phenoxyphenyl nicotinyl ketone.
- 18. A method of obtaining a hypolipidemic effect in a mammal in need of such treatment, which comprises administering orally or parenterally to said mammal a hypolepidemic-effective amount of a compound which is a member of the group consisting of a free organic base of the formula: ##STR18## wherein R.sup.1 is a hydrogen atom, alkyl having from 1 to 4 carbons, fluoro or chloro;
- R.sup.2 is a hydrogen atom, alkyl having from 1 to 4 carbons, alkoxy having from 1 to 4 carbons, fluoro or chloro;
- R.sup.3 is a hydrogen atom, alkyl having from 1 to 4 carbons, alkoxy having from 1 to 4 carbons, fluoro or chloro;
- A is either ##STR19## in which R.sup.4 is a hydrogen atom or alkyl having from 1 to 4 carbon atoms, and
- B is an unsubstituted pyridyl radical which may be attached at its 2-, 3- or 4- position, and a
- pharmaceutically acceptable acid addition salt thereof; provided that when R.sup.2 and R.sup.3 are on adjacent carbons they are not both alkyl or alkoxy which are branched.
- 19. A method of claim 18 in which B of the compound is a 3-pyridyl radical and R.sup.4 is a hydrogen atom.
- 20. A method of claim 18 in which R.sup.4 of the compound is a hydrogen atom.
- 21. A method of claim 18 in which the compound is administered in a total daily dosage of from about 300 to 3000 milligrams.
- 22. A method of claim 18 in which the compound is administered orally.
- 23. A method of claim 18 in which the compound is administered in admixture with a pharmaceutically acceptable solid carrier.
- 24. A method of claim 18 in which the compound is p-phenoxyphenyl nicotinyl ketone.
- 25. The method of claim 18 in which the compound is p-(p-tertiary butylphenoxy)phenyl 4-pyridyl carbinol.
- 26. A method of claim 18 in which A of the compound is of type a).
- 27. A method of claim 18 in which A of the compound is of type b).
Parent Case Info
This is a continuation-in-part of copending application Ser. No. 623,754 (filed Oct. 20, 1975); now abandoned whch in turn is a continuation-in-part of then copending application Ser. No. 573,856 (filed May 2, 1975; now abandoned) which in turn is a continuation-in-part of then copending application Ser. No. 553,997 (filed Feb. 28, 1975; now abandoned).
US Referenced Citations (4)
Non-Patent Literature Citations (1)
Entry |
Sam et al., Journal of Pharmaceutical Sciences, vol. 60, pp. 936 to 939 (1971). |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
623754 |
Oct 1975 |
|
Parent |
573856 |
May 1975 |
|
Parent |
553997 |
Feb 1975 |
|